UNITED GUARDIAN INC - 10-K Summary (Fiscal Year Ended Dec 31, 2010)
Business Context and Reporting Period
Company: United-Guardian, Inc. (Ticker: UG)
Reporting Period: Fiscal year ended December 31, 2010
Business Overview: A Delaware corporation manufacturing and marketing cosmetic ingredients, personal care products, pharmaceuticals, medical products, and specialty industrial products. The company operates in a single business segment with a primary facility in Hauppauge, New York.
Key Products: The LUBRAJEL® line (cosmetic ingredients/medical lubricants) and RENACIDIN® (pharmaceutical irrigation solution) accounted for approximately 95% of total revenue in 2010.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Net Sales | $13,723,074 | $13,276,984 |
| Net Income | $3,799,692 | $3,878,963 |
| Earnings Per Share (Basic/Diluted) | $0.80 | $0.78 |
| Gross Margin | 61.7% | 59.9% |
| Operating Cash Flow | $4,093,318 | $4,337,448 |
| Working Capital | $11,765,995 | $14,735,891 |
| Current Ratio | 12.5:1 | 6.0:1 |
| Total Assets | $14,074,739 | $18,716,292 |
| Long-Term Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by 3.4% ($446,090) driven by a 5.2% increase in personal care products sales, offset by a 4.4% decline in pharmaceutical sales.
- Pharmaceutical Shortage: Sales of RENACIDIN® declined due to a temporary suspension of production by the contract manufacturer in August 2010. This resulted in a 60% reduction in monthly sales starting November 2010 and an estimated $150,000 loss in 2010 revenue.
- Pension Plan Termination: The company terminated its defined benefit pension plan in July 2010, incurring a one-time before-tax charge of $847,744 (after-tax charge of $559,133).
- Share Repurchase: The company acquired 350,000 shares of common stock from its President and largest shareholder for $3,762,500, significantly reducing working capital and outstanding shares.
- Margin Expansion: Cost of sales as a percentage of net sales decreased to 38.3% from 40.1%, improving gross margins due to a shift toward higher-margin products.
Guidance, Outlook, and Risks
- Production Outlook: Management projects RENACIDIN® production will resume in April 2011, with normal shipments expected in May 2011. The company estimates total lost gross sales from the shortage at approximately $550,000.
- Legal Action: The company has notified its supplier of a breach of supply agreement regarding the RENACIDIN® shortage and intends to hold the supplier responsible for lost business and expenses.
- Market Risks: The company faces competition, particularly from new products produced in China. Sales of LUBRAJEL® depend heavily on marketing partners, specifically International Specialty Products Inc. (ISP).
- Liquidity: Despite a decrease in working capital due to the stock buyback, the company maintains a strong current ratio of 12.5:1 and believes its capital resources are sufficient for the next fiscal year. No line of credit is maintained.
- Dividends: The company paid three dividends in 2010 totaling $0.63 per share ($0.30 in June and $0.33 in December), compared to two dividends in 2009.
Investor Verification Checklist
- RENACIDIN® Supply Chain: Verify the resumption of production and the status of the legal claim against the contract manufacturer.
- Customer Concentration: Confirm the stability of relationships with the top two customers, who accounted for 53% of 2010 revenues.
- Stock Repurchase Impact: Assess the long-term capital allocation strategy following the $3.76M buyback from the President.
- Marketing Partner Performance: Monitor sales trends with ISP and other international distributors, particularly in Europe and Asia.
- Patent Expirations: Review the impact of expiring patents on the LUBRAJEL® line (specifically the radiation-resistant patent expiring in 2013).